Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data

다국어 초록 (Multilingual Abstract)

ObjectiveaaSecond-generation antipsychotics have been repeatedly shown to be superior to placebo. However, the comparative efficacy among these drugs has not been systematically evaluated. In this study, we used Mixed Treatment Comparison (MTC) procedures to elucidate the comparative efficacy and tolerability of second-generation antipsychotics.
MethodsaaSeven antipsychotics were selected based on the availability of the relevant data. Data were gathered from a series of review article published by the Cochrane Collaboration. Six outcome measures were analyzed: 1) percentage of no clinically important response as defined by the original authors, 2) PANSS total score change from baseline to endpoint, 3) percentage of akathisia, 4) percentage of antiparkinson medication use, 5) percentage of total body weight increase more than 7%, and 6) percentage of drop-out due to any reasons.
ResultsaaAll the second-generation antipsychotics included in this study showed fairly similar efficacy but widely different tolerability. In terms of efficacy, amisulpride, clozapine and olanzapine were ranked higher than aripiprazole, quetiapine and ziprasidone. Clozapine and olanzapine were superior in terms of akathisia and extrapyramidal symptom risk, but, far more prone to induce clinically important weight gain.
ConclusionaaUsing MTC methodology, we could line up the second generation antipsychotics according to their hierarchical superiority in terms of efficacy and tolerability. Though the wide overlap among the confidence intervals and the inconsistency between the direct and indirect comparison results may limit the validity of these results, it may still allow the important insights into the relative merits of the available drugs.

참고문헌 (Reference)

1 Subramanian S, "Zotepine versus other atypical antipsychotics for schizophrenia" CD006628-, 2010

2 Komossa K, "Zotepine versus other atypical antipsychotics for schizophrenia" CD006628-, 2010

3 Komossa K, "Ziprasidone versus other atypical antipsychotics for schizophrenia" CD006627-, 2009

4 Lunn DJ, "WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility" 10 : 325-337, 2000

5 Kemp AS, "What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?" 36 : 504-509, 2010

6 Cipriani A, "What is a multiple treatments meta-analysis?" 21 : 151-153, 2012

7 Bucher HC, "The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials" 50 : 683-691, 1997

8 Fava M, "The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach" 72 : 115-127, 2003

9 Mills EJ, "The effects of excluding treatments from network meta-analyses: survey" 347 : f5195-, 2013

10 Komossa K, "Sertindole versus other atypical antipsychotics for schizophrenia" CD006752-, 2009

11 Komossa K, "Risperidone versus other atypical antipsychotics for schizophrenia" CD006626-, 2011

12 Komossa K, "Quetiapine versus other atypical antipsychotics for schizophrenia" CD006625-, 2010

13 Alphs L, "Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?" 15 : 1003-1014, 2012

14 Komossa K, "Olanzapine versus other atypical antipsychotics for schizophrenia" CD006654-, 2010

15 Scarff JR, "Newer oral atypical antipsychotic agents: a review" 36 : 832-838, 2011

16 Enck P, "New insights into the placebo and nocebo responses" 59 : 195-206, 2008

17 Lumley T, "Network meta-analysis for indirect treatment comparisons" 21 : 2313-2324, 2002

18 Assiri A, "Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation" 35 : 967-984, 2013

19 Caldwell DM, "Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency" 63 : 875-882, 2010

20 Sobieraj DM, "Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review" 3 : 2013

21 Jansen JP, "Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes" 12 : 152-, 2012

22 Plummer M, "JAGS Version 1.0. 3 manual"

23 Hrobjartsson A, "Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment" 256 : 91-100, 2004

24 Ioannidis JP, "Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses" 181 : 488-493, 2009

25 Salanti G, "Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial" 64 : 163-171, 2011

26 Brooks SP, "General methods for monitoring convergence of iterative simulations" 7 : 434-455, 1998

27 Rosenberg W, "Evidence based medicine: an approach to clinical problem-solving" 310 : 1122-1126, 1995

28 Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia" 353 : 1209-1223, 2005

29 Hoaglin DC, "Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2" 14 : 429-437, 2011

30 Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis" 382 : 951-962, 2013

31 Cipriani A, "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis" 373 : 746-758, 2009

32 Asenjo Lobos C, "Clozapine versus other atypical antipsychotics for schizophrenia" CD006633-, 2010

33 Dias S, "Checking consistency in mixed treatment comparison meta-analysis" 29 : 932-944, 2010

34 Valkenhoef G, "Automating network meta-analysis" 3 : 285-299, 2012

35 Komossa K, "Aripiprazole versus other atypical antipsychotics for schizophrenia" CD006569-, 2009

36 Khanna P, "Aripiprazole versus other atypical antipsychotics for schizophrenia" 2 : CD006569-, 2013

37 Komossa K, "Amisulpride versus other atypical antipsychotics for schizophrenia" CD006624-, 2010

38 Haddad PM, "Adverse effects of atypical antipsychotics: differential risk and clinical implications" 21 : 911-936, 2007

39 Takeuchi H, "A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder" 228 : 175-185, 2013

40 Klemp M, "A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo" 31 : 698-704, 2011

41 Tu YK, "A primer on network meta-analysis for dental research" 2012 : 276520-, 2012

42 Kerwin R, "A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study" 22 : 433-443, 2007

43 Davis JM, "A meta-analysis of the efficacy of second-generation antipsychotics" 60 : 553-564, 2003

44 Leucht S, "A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia" 166 : 152-163, 2009